The George Institute For Global Health
Global
United Kingdom
India
China
Australia

Thrombin Receptor Antagonist in the Secondary prevention of atherothrombotic ischaemic events (TRA2P)

Project status: 
Archived

It evaluates the safety and efficacy of SCH 530348 (Thrombin Receptor Antagonist) in addition to standard of care in subjects with a history of atherosclerotic disease(Secondary Prevention of Atherothrombotic Ischaemic Events).